{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:21:48Z","timestamp":1784276508319,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012541","name":"Guangdong Innovative and Entrepreneurial Research Team Program","doi-asserted-by":"publisher","award":["2017ZT07S096"],"award-info":[{"award-number":["2017ZT07S096"]}],"id":[{"id":"10.13039\/100012541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41375-021-01266-6","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:03:54Z","timestamp":1620965034000},"page":"2616-2620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-881X","authenticated-orcid":false,"given":"Chong-xiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao-jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-8135","authenticated-orcid":false,"given":"Le-tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-9580","authenticated-orcid":false,"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Can\u00e8 S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Investig. 2020;130:6409\u201316.","journal-title":"J Clin Investig"},{"key":"1266_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81:318\u201356.","journal-title":"J Infect"},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","volume":"60","author":"JL Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology. 2021;60:399\u2013407.","journal-title":"Rheumatology"},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020;81:647\u201379.","journal-title":"J Infect"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","volume":"146","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146:137\u201346.e133.","journal-title":"J Allergy Clin Immunol"},{"key":"1266_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3389\/fphar.2020.00857","volume":"11","author":"V Giudice","year":"2020","unstructured":"Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857.","journal-title":"Front Pharmacol"},{"key":"1266_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41375-020-01087-z","volume":"35","author":"A D\u2019Alessio","year":"2021","unstructured":"D\u2019Alessio A, Del Poggio P, Bracchi F, Cesana G, Sertori N, Di Mauro D, et al. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia. 2021;35:635\u20138.","journal-title":"Leukemia"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"ofaa563","DOI":"10.1093\/ofid\/ofaa563","volume":"7","author":"M Falcone","year":"2020","unstructured":"Falcone M, Tiseo G, Barbieri G, Galfo V, Russo A, Virdis A, et al. Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observational study. Open Forum Infect Dis. 2020;7:ofaa563.","journal-title":"Open Forum Infect Dis"},{"key":"1266_CR10","doi-asserted-by":"crossref","unstructured":"Rosas J, Lia\u00f1o FP, Cant\u00f3 ML, Barea JMC, Beser AR, Rabasa JTA, et al. Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: a real-world study. Reumatol Clin. 2020;S1699-258X:30271-0.","DOI":"10.1016\/j.reuma.2020.10.009"},{"key":"1266_CR11","doi-asserted-by":"crossref","unstructured":"Stebbing J, S\u00e1nchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7:eabe4724.","DOI":"10.1126\/sciadv.abe4724"},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","volume":"34","author":"F La Ros\u00e9e","year":"2020","unstructured":"La Ros\u00e9e F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805\u201315.","journal-title":"Leukemia"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/s41375-020-0898-6","volume":"34","author":"F Heidel","year":"2020","unstructured":"Heidel F, Hochhaus A. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation. Leukemia. 2020;34:1723\u20135.","journal-title":"Leukemia"},{"key":"1266_CR14","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41375-020-01038-8","volume":"34","author":"A Gozzetti","year":"2020","unstructured":"Gozzetti A, Capochiani E, Bocchia M. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19. Leukemia. 2020;34:2815\u20136.","journal-title":"Leukemia"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/s41375-020-0907-9","volume":"34","author":"A Neubauer","year":"2020","unstructured":"Neubauer A, Wiesmann T, Vogelmeier CF, Mack E, Skevaki C, Gaik C, et al. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2020;34:2276\u20138.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01266-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01266-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01266-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:11:14Z","timestamp":1630487474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01266-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01266-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RPG is a consultant to BeiGene Ltd, Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., and CStone Pharmaceuticals. Advisor: Antegene Biotech LLC, Medical Director: FFF Enterprises Inc. Partner: AZACA Inc. Board of Directors: RakFond Foundation for Cancer Research Support. Scientific Advisory Board, StemRad Ltd. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}